Literature DB >> 10364355

Induction of adult T-cell leukemia-like lymphoproliferative disease and its inhibition by adoptive immunotherapy in T-cell-deficient nude rats inoculated with syngeneic human T-cell leukemia virus type 1-immortalized cells.

T Ohashi1, S Hanabuchi, H Kato, Y Koya, F Takemura, K Hirokawa, T Yoshiki, Y Tanaka, M Fujii, M Kannagi.   

Abstract

Human T-cell leukemia virus type 1 (HTLV-1) has been shown to be the etiologic agent of adult T-cell leukemia (ATL), but the in vivo mechanism by which the virus causes the malignant transformation is largely unknown. In order to investigate the mechanisms of HTLV-1 leukemogenesis, we developed a rat model system in which ATL-like disease was reproducibly observed, following inoculation of various rat HTLV-1-immortalized cell lines. When previously established cell lines, F344-S1 and TARS-1, but not TART-1 or W7TM-1, were inoculated, systemic multiple tumor development was observed in adult nude (nu/nu) rats. FPM1 cells, newly established from a heterozygous (nu/+) rat syngeneic to nu/nu rats, caused transient tumors only at the injection site in adult nu/nu rats, but could progressively grow in newborn nu/nu rats and metastasize in lymph nodes. The derivative cell line (FPM1-V1AX) serially passed through newborn nu/nu rats acquired the potency to grow in adult nu/nu rats. These results indicated that only some with additional changes but not all of the in vitro HTLV-1-immortalized cell lines possessed in vivo tumorigenicity. Using the syngeneic system, we further showed the inhibition of tumor development by transferring splenic T cells from immunized rats, suggesting the involvement of T cells in the regression of tumors. This novel and reproducible nude rat model of human ATL would be useful for investigation of leukemogenesis and antitumor immune responses in HTLV-1 infection.

Entities:  

Mesh:

Year:  1999        PMID: 10364355      PMCID: PMC112664     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Variation in the clinical courses of adult T-cell leukemia.

Authors:  F Kawano; K Yamaguchi; H Nishimura; H Tsuda; K Takatsuki
Journal:  Cancer       Date:  1985-02-15       Impact factor: 6.860

2.  HTLV-I associated myelopathy, a new clinical entity.

Authors:  M Osame; K Usuku; S Izumo; N Ijichi; H Amitani; A Igata; M Matsumoto; M Tara
Journal:  Lancet       Date:  1986-05-03       Impact factor: 79.321

3.  Direct activation of resting T lymphocytes by human T-lymphotropic virus type I.

Authors:  L Gazzolo; M Duc Dodon
Journal:  Nature       Date:  1987 Apr 16-22       Impact factor: 49.962

4.  Experimental infection of rabbits with human T-cell leukemia virus type I.

Authors:  T Akagi; I Takeda; T Oka; Y Ohtsuki; S Yano; I Miyoshi
Journal:  Jpn J Cancer Res       Date:  1985-02

5.  Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis.

Authors:  A Gessain; F Barin; J C Vernant; O Gout; L Maurs; A Calender; G de Thé
Journal:  Lancet       Date:  1985-08-24       Impact factor: 79.321

6.  Immortalization of peripheral blood lymphocytes of cats by human T-cell leukemia virus.

Authors:  H Hoshino; H Tanaka; K Shimotohno; M Miwa; M Nagai; M Shimoyama; T Sugimura
Journal:  Int J Cancer       Date:  1984-10-15       Impact factor: 7.396

7.  A proposal for smoldering adult T-cell leukemia: a clinicopathologic study of five cases.

Authors:  K Yamaguchi; H Nishimura; H Kohrogi; M Jono; Y Miyamoto; K Takatsuki
Journal:  Blood       Date:  1983-10       Impact factor: 22.113

8.  Establishment of human cytotoxic T cell lines specific for human adult T cell leukemia virus-bearing cells.

Authors:  M Kannagi; K Sugamura; H Sato; K Okochi; H Uchino; Y Hinuma
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

9.  Experimental inoculation of monkeys with autologous lymphoid cell lines immortalized by and producing human T-cell leukemia virus type-I.

Authors:  H Nakamura; Y Tanaka; A Komuro-Tsujimoto; K Ishikawa; K Takadaya; H Tozawa; H Tsujimoto; S Honjo; M Hayami
Journal:  Int J Cancer       Date:  1986-12-15       Impact factor: 7.396

10.  Specific cytolysis of fresh tumor cells by an autologous killer T cell line derived from an adult T cell leukemia/lymphoma patient.

Authors:  M Kannagi; K Sugamura; K Kinoshita; H Uchino; Y Hinuma
Journal:  J Immunol       Date:  1984-08       Impact factor: 5.422

View more
  18 in total

1.  Mouse models of human T lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma.

Authors:  B Zimmerman; S Niewiesk; M D Lairmore
Journal:  Vet Pathol       Date:  2010-05-04       Impact factor: 2.221

2.  Development of human T-cell leukemia virus type 1-transformed tumors in rats following suppression of T-cell immunity by CD80 and CD86 blockade.

Authors:  S Hanabuchi; T Ohashi; Y Koya; H Kato; F Takemura; K Hirokawa; T Yoshiki; H Yagita; K Okumura; M Kannagi
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 3.  Animal models for human T-lymphotropic virus type 1 (HTLV-1) infection and transformation.

Authors:  Michael D Lairmore; Lee Silverman; Lee Ratner
Journal:  Oncogene       Date:  2005-09-05       Impact factor: 9.867

4.  Depletion of dendritic cells enhances susceptibility to cell-free infection of human T cell leukemia virus type 1 in CD11c-diphtheria toxin receptor transgenic mice.

Authors:  Saifur Rahman; Sharrón L Manuel; Zafar K Khan; Brian Wigdahl; Edward Acheampong; Frederic Tangy; Pooja Jain
Journal:  J Immunol       Date:  2010-04-09       Impact factor: 5.422

5.  Rat CRM1 is responsible for the poor activity of human T-cell leukemia virus type 1 Rex protein in rat cells.

Authors:  Y Hakata; M Yamada; H Shida
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

6.  In vitro peptide immunization of target tax protein human T-cell leukemia virus type 1-specific CD4+ helper T lymphocytes.

Authors:  Hiroya Kobayashi; Toshihiro Ngato; Keisuke Sato; Naoko Aoki; Shoji Kimura; Yuetsu Tanaka; Hitoshi Aizawa; Masatoshi Tateno; Esteban Celis
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

7.  Murine FLT3 ligand-derived dendritic cell-mediated early immune responses are critical to controlling cell-free human T cell leukemia virus type 1 infection.

Authors:  Saifur Rahman; Zafar K Khan; Brian Wigdahl; Stephen R Jennings; Frederic Tangy; Pooja Jain
Journal:  J Immunol       Date:  2010-11-29       Impact factor: 5.422

Review 8.  Molecular biology and pathogenesis of the human T-cell leukaemia/lymphotropic virus Type-1 (HTLV-1).

Authors:  J M Johnson; R Harrod; G Franchini
Journal:  Int J Exp Pathol       Date:  2001-06       Impact factor: 1.925

9.  Cyclosporine-induced immune suppression alters establishment of HTLV-1 infection in a rabbit model.

Authors:  Rashade A H Haynes; Evan Ware; Christopher Premanandan; Bevin Zimmerman; Lianbo Yu; Andrew J Phipps; Michael D Lairmore
Journal:  Blood       Date:  2009-11-20       Impact factor: 22.113

10.  Correlation of major histocompatibility complex class I downregulation with resistance of human T-cell leukemia virus type 1-infected T cells to cytotoxic T-lymphocyte killing in a rat model.

Authors:  Takashi Ohashi; Shino Hanabuchi; Reiko Suzuki; Hirotomo Kato; Takao Masuda; Mari Kannagi
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.